Comparative Pharmacology
Head-to-head clinical analysis: CRESEMBA versus DIFLUCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESEMBA versus DIFLUCAN.
CRESEMBA vs DIFLUCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isavuconazole, the active moiety of CRESEMBA, inhibits fungal cytochrome P450-dependent 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, disrupting fungal cell membrane synthesis and function.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
200 mg intravenously every 8 hours for the first 48 hours (6 doses), then 200 mg intravenously once daily; or 200 mg orally three times daily for the first 48 hours (6 doses), then 200 mg orally once daily.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, supporting once-daily dosing; steady-state achieved by Day 4-5.
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Fecal: ~76% (primarily as unchanged drug); Renal: <1% (unchanged); Biliary: Not a major route; Metabolism via CYP3A4 to inactive metabolites eliminated fecally.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Category C
Category C
Antifungal
Antifungal